GEN1044

DuoBody-CD3x5T4 · Genmab

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GEN1044, covering 2023-02-01 to 2023-02-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors [Phase 1, Phase 2]